Clinical Gastroenterology and Hepatology·2 hWeight changes differentially impact MASLD incidence, progression and outcomes based on genetic and metabolic risk profilesCohort study of 11,882 peoplePopulationsPaper
Journal of Hepatology·29 SepEASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted TherapyReviewIndustry & policyPaper
Digestion·9 SepSemaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's MissingReviewTirzepatidePaper
Nature·3 SepCurrent therapeutic landscape and future treatment perspectives of MASHReviewInterventionsPaper